A phase IIa, double-blind, randomised, vehicle-controlled trial of MOL 4249 for the treatment of mild-to-moderate plaque psoriasis.
Latest Information Update: 15 Oct 2013
At a glance
- Drugs MOL 4249 (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Moleculin
- 15 Oct 2013 New trial record
- 29 Sep 2013 Results have been reported in a Moleculin media release